Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Diabetes medication may lower heart attack and stroke risk by curbing platelet overactivation (opens in a new tab)

medicalxpress.com · 2026-10-28

Short answerEvidenceSource

Short answer

Mostly supported

Mostly supported.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 4 supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mostly supported

Every claim we could check holds up. Four of five claims match the study. This overall rating is based only on the claims we could check. One claim the study doesn't address.

  • 4 supported
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredIn mice with injured blood vessels, sotagliflozin reduced clot formation by approximately 60%, compared with just 5%–10% in animals treated with empagliflozin.View evidenceHide evidence

As statedapproximately 60%; 5%–10%

Why this verdict

The abstract-level profile supports the qualitative direction: in vivo mouse models showed sotagliflozin reduced platelet activity/thrombus formation while empagliflozin had minor to no effects. However, the abstract profile does not provide the claimed injured-vessel model details or the quantitative magnitudes of approximately 60% versus 5%–10%, so those specifics are not verifiable at abstract depth.

1

Study evidence

Sotagliflozin inhibited platelet activity and reduced thrombus formation in in vivo mouse models.

“Employing ex vivo models using blood from healthy donors or T2DM patients, and in vivo mouse models, we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”
Claim 2 of 5SupportedResearchers at Michigan Medicine uncovered a mechanism that may explain why sotagliflozin reduces the risk of heart attack and stroke.View evidenceHide evidence

Why this verdict

The abstract-level profile states that sotagliflozin has been associated in clinical trials with reduced myocardial infarction and stroke, and that this study investigated platelet/thrombus mechanisms that may explain that protection. The story’s wording is hedged as a possible mechanism, which matches the paper framing. The supplied profile does not independently verify the Michigan Medicine affiliation, but the scientific claim is supported.

1

Study evidence

Sotagliflozin produced an inhibitory effect on platelet activity and thrombus formation in ex vivo assays using human blood from healthy donors and T2DM patients.

“Employing ex vivo models using blood from healthy donors or T2DM patients... we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”
2

Study evidence

Sotagliflozin inhibited platelet activity and reduced thrombus formation in in vivo mouse models.

“Employing ex vivo models using blood from healthy donors or T2DM patients, and in vivo mouse models, we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”
Claim 3 of 5SupportedThe findings were published in the Journal of Clinical Investigation and are presented as evidence that sotagliflozin may offer protection against blood clots beyond blood sugar control.View evidenceHide evidence

Why this verdict

The scientific framing is supported: the paper presents sotagliflozin’s direct effects on platelet activation and thrombus formation as a potential antithrombotic mechanism beyond glucose lowering. The claim is appropriately hedged with 'may.' The supplied scientific profile does not independently encode the Journal of Clinical Investigation publication venue, but the paper-evidence portion of the claim is supported.

1

Study evidence

Sotagliflozin produced an inhibitory effect on platelet activity and thrombus formation in ex vivo assays using human blood from healthy donors and T2DM patients.

“Employing ex vivo models using blood from healthy donors or T2DM patients... we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”
2

Study evidence

Sotagliflozin inhibited platelet activity and reduced thrombus formation in in vivo mouse models.

“Employing ex vivo models using blood from healthy donors or T2DM patients, and in vivo mouse models, we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”
Claim 4 of 5SupportedIn laboratory experiments, sotagliflozin helped prevent excessive platelet activation, a process that can lead to dangerous blood clots that block flow to the heart and brain.View evidenceHide evidence

Why this verdict

The paper profile reports ex vivo human blood/platelet experiments in which sotagliflozin inhibited platelet activity and thrombus formation. Because the story locates the effect in laboratory experiments, its causal wording is acceptable for the experimental assay context, rather than claiming proven prevention of human clinical events.

1

Study evidence

Sotagliflozin produced an inhibitory effect on platelet activity and thrombus formation in ex vivo assays using human blood from healthy donors and T2DM patients.

“Employing ex vivo models using blood from healthy donors or T2DM patients... we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”
Claim 5 of 5SupportedThe article says sotagliflozin limited platelet activation in blood samples from healthy volunteers and people with type 2 diabetes, while empagliflozin had little to no effect.View evidenceHide evidence

Why this verdict

This closely matches the abstract statement that ex vivo models used blood from healthy donors and T2DM patients and showed inhibitory effects of sotagliflozin on platelet activity/thrombus formation, while empagliflozin had minor to no effects.

1

Study evidence

Sotagliflozin produced an inhibitory effect on platelet activity and thrombus formation in ex vivo assays using human blood from healthy donors and T2DM patients.

“Employing ex vivo models using blood from healthy donors or T2DM patients... we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Mouse hemostasis assessments found no observed impairment of hemostasis with sotagliflozin.

    This safety/physiology result is a distinct abstract-level paper element, but it is not included in the supplied story claims or caveats.

    From in_vivo_mouse_hemostasis_assays

  • Platelet-specific SGLT1 deletion in mice reduced platelet integrin activation and thrombus formation, supporting platelet SGLT1 as a mechanistic driver.

    The story generally mentions a mechanism, but it does not reflect the specific genetic knockout evidence involving platelet-specific SGLT1 deletion and integrin activation.

    From platelet-specific Slc5a1 knockout (Slc5a1fl/fl; Gp1ba-Cre+)

  • At abstract depth, key methodological and statistical details are unavailable, including sample sizes, drug concentrations, assay parameters, exact mouse model details, p values, and quantitative effect sizes.

    The story does not mention these abstract-level evidentiary limitations. This matters especially for the story’s specific quantitative mouse-effect claim, which cannot be verified from the abstract profile.

    From ex_vivo_human_platelet_assays; in vivo mouse thrombosis experiments (drug comparison); in_vivo_mouse_hemostasis_assays;

3 things the story did carry across
  • Ex vivo human blood assays from healthy donors and patients with type 2 diabetes showed sotagliflozin inhibited platelet activation and thrombus formation, while empagliflozin had minor to no effects.
  • In vivo mouse thrombosis models showed sotagliflozin reduced platelet activity/thrombus formation, with empagliflozin showing minor to no effects.
  • The evidence in the article is mechanistic, ex vivo, and animal-model evidence rather than a new clinical outcomes trial showing reduced heart attack or stroke events.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

ex vivo human

1Lead resultex vivo humanSotagliflozin (dual SGLT1/2 inhibitor) directly attenuates platelet activation and thrombus formation more than the SGLT2-selective inhibitor empagliflozin, based on ex vivo assays using human blood.ex vivo human platelet assaysExpand

In plain English

In ex vivo assays using human whole blood or platelets from healthy donors and patients with T2DM, sotagliflozin (dual SGLT1/2 inhibitor) produced an inhibitory effect on platelet activity and thrombus formation, whereas the SGLT2-selective inhibitor empagliflozin showed minor to no effects; the abstract additionally reports no observed impact of sotagliflozin on hemostasis.

Key findings

  • Sotagliflozin produced an inhibitory effect on platelet activity and thrombus formation in ex vivo assays using human blood from healthy donors and T2DM patients.
  • Empagliflozin showed minor to no effects on platelet activity and thrombus formation in the same ex vivo human assays.
“Employing ex vivo models using blood from healthy donors or T2DM patients... we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

2in vivo animalSotagliflozin reduces thrombosis in vivo without impairing hemostasis, based on mouse models.in vivo mouse thrombosis experiments (drug comparison)Expand

In plain English

In in vivo mouse models, sotagliflozin inhibited platelet activity and reduced thrombus formation without affecting hemostasis, whereas the SGLT2-selective inhibitor empagliflozin showed minor to no effect on these endpoints.

Key findings

  • Sotagliflozin inhibited platelet activity and reduced thrombus formation in in vivo mouse models.
  • Empagliflozin showed minor to no effect on platelet activity and thrombus formation in the same in vivo mouse models.
“Employing ex vivo models using blood from healthy donors or T2DM patients, and in vivo mouse models, we demonstrate an inhibitory effect on platelet activity and thrombus formation with sotagliflozin, while empagliflozin has minor to no effects.”
What this piece can’t prove
  • This summary is based only on the abstract; the abstract does not report experimental details (mouse model type, thrombosis induction method, dosing, timing, sample sizes, or statistics).

2 further details could not be confirmed from the summary.

3in vivo animalSotagliflozin reduces thrombosis in vivo without impairing hemostasis, based on mouse models.in vivo mouse hemostasis assaysExpand

In plain English

Abstract reports that sotagliflozin inhibited platelet activity and thrombus formation in ex vivo and in vivo models and that, in mouse hemostasis assessments, sotagliflozin had no impact on hemostasis.

Key findings

  • No impact on hemostasis was observed with sotagliflozin in mouse hemostasis/bleeding assessments.
  • Sotagliflozin inhibited platelet activation and thrombus formation in ex vivo human blood and in vivo mouse models; empagliflozin showed minor to no effects.
“Further, no impact on hemostasis was observed with sotagliflozin.”
What this piece can’t prove
  • Summary is based solely on the abstract; full methods, numeric results, sample sizes, and statistical analyses are not available here.
  • Abstract does not specify the specific mouse hemostasis assays, dosing regimen, timing, mouse strain, or comparator details for the hemostasis assessments.
  • No quantitative bleeding metrics or thresholds reported; cannot assess magnitude or precision of 'no impact' conclusion.

2 further details could not be confirmed from the summary.

4in vivo animalPlatelet SGLT1 is a mechanistic driver of platelet activation/thrombosis: platelet-specific SGLT1 deletion reduces integrin activation and thrombus formation.platelet-specific Slc5a1 knockout (Slc5a1fl/fl; Gp1ba-Cre+)Expand

In plain English

The paper reports that platelet-specific genetic deletion of SGLT1 (Slc5a1fl/fl; Gp1ba-Cre+) in mice resulted in reduced platelet integrin activation and reduced thrombus formation, indicating platelet SGLT1 contributes to platelet activation and thrombosis. The abstract does not provide quantitative effect sizes, sample sizes, genotyping/controls, or statistical details.

Key findings

  • Platelet-specific deletion of SGLT1 (Slc5a1fl/fl; Gp1ba-Cre+) reduced platelet integrin activation in mice.
  • Platelet-specific deletion of SGLT1 (Slc5a1fl/fl; Gp1ba-Cre+) reduced thrombus formation in vivo.
“Finally, a platelet-specific deletion of SGLT1 via Slc5a1fl/fl Gp1ba-Cre+ mice resulted in reduced platelet integrin activation and thrombus formation.”
What this piece can’t prove
  • Abstract does not provide genotyping, recombination efficiency, controls, sample sizes, or replication details for the platelet-specific knockout experiments.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Crossref · 15 candidate papers

Candidate

SOTAGLIFLOZIN, A DUAL SGLT1/2 INHIBITOR, UNLIKE THE SELECTIVE SGLT2 INHIBITOR EMPAGLIFLOZIN, INHIBITS HUMAN PLATELET ACTIVATION AND IN VIVO THROMBUS FORMATION

Journal of the American College of Cardiology · 2025 · Crossref

Source (opens in a new tab)
Candidate

Abstract 4134384: Sotagliflozin, a Dual Inhibitor of Sodium-Glucose Transporters 1 and 2, Elicits Cardioprotective Effects Through Attenuation of Platelet Activation and Thrombosis

Circulation · 2024 · Crossref

Source (opens in a new tab)
Candidate

Platelet PAR1 receptor density—Correlation to platelet activation response and changes in exposure after platelet activation

Thrombosis Research · 2008 · Crossref

Source (opens in a new tab)
Candidate

Activation and inhibition of platelet aggregation by two distinct anti-human platelet monoclonal antibodies

Thrombosis Research · 1986 · Crossref

Source (opens in a new tab)
Candidate

Comparison of the Anti-Platelet and Anti-Thrombotic Effects of the Dual SGLT1/2 Inhibitor Sotagliflozin to the Relatively Selective SGLT2 Inhibitor Empagliflozin

Blood · 2024 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.